Navigation Links
Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R)
Date:5/8/2009

EXTON, Pa., May 8 /PRNewswire/ -- BioTrends Research Group released highlights from its baseline wave of LaunchTrends(TM): SIMPONI, a four wave syndicated research study that will track uptake of the drug from FDA approval through six months post launch. The research is based on results of a survey of 77 Rheumatologists conducted on-line between May 5th and May 7th.

95% of the Rheumatologists surveyed were aware of SIMPONI and about one-third had been called on by SIMPONI sales representatives. Two-thirds reported a favorable reaction to SIMPONI and 83% reported a high interest in learning more about the product. Among those familiar with SIMPONI, nearly all were aware of the monthly dosing intervals, but overall the respondents were less familiar with the product's indications and dose delivery forms. Compared to the other biologics indicated for RA, 43% identified SIMPONI as the "easiest to administer/easiest for patients to take" while 26% gave Abbott's HUMIRA(R) top billing for ease of use. The respondents reported that close to 40% of their severe RA patients could be considered candidates for SIMPONI and that the majority of SIMPONI patients would be switched from other biologic agents. Market share projections suggest that SIMPONI will primarily draw from other TNF-inhibitors and 38% of the respondents suggest that they will prescribe the product for their RA patients as soon as it is available.

Surveyed Rheumatologists are also highly aware of other late stage biologics awaiting approval such as UCB's CIMZIA(R) and Roche's ACTEMRA(R). 62% of the respondents reported a greater interest in ACTEMRA compared to SIMPONI, primarily due to ACTEMRA's novel mechanism of action. Given a choice between SIMPONI and CIMZIA, the respondents reported a greater interest in SIMPONI by a 3:1 margin.

About SIMPONI

Centocor Ortho Biotech, Inc. received FDA approval for SIMPONI(R) (generic name: golimumab) on April 24, 2009. The first once-monthly subcutaneous anti-TNF-alpha therapy, SIMPONI is approved for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis. The product will be available in two dosing delivery forms: the SIMPONI SmartJect autoinjector and a prefilled syringe.

LaunchTrends: SIMPONI is a four wave primary market research study that consists of a quantitative on-line survey and qualitative telephone interviews. In total, 300 Rheumatologists will participate in the research. Following a baseline report, three additional waves will be published capturing launch effectiveness at one month, three months, and six months post launch. The reports are designed to assess trial and use of SIMPONI(R), obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other agents. The full baseline report, which incorporates quantitative and qualitative results, will be published on May 22, 2009.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or http://www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):